4-(2-aminopyridin-4-yl)benzaldehyde | 622402-34-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-(2-aminopyridin-4-yl)benzaldehyde
• CAS: 622402-34-0
• 化学式: C₁₂H₁₀N₂O
• 分子量: 198.224
• InChiKey: ZFWUINFXVDXURB-UHFFFAOYSA-N

物化性质

• 沸点：
  411.5±40.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-aminopyridin-4-yl)benzaldehyde 在 四(三苯基膦)钯 、 一氯化碘 、 碳酸氢钠 、 sodium carbonate 、 溶剂黄146 作用下， 以 1,4-二氧六环 为溶剂， 生成 4-(3-Phenyl-imidazo[1,2-a]pyridin-7-yl)-benzaldehyde
  参考文献：
  名称：

  Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

  摘要：

  3,7-Diaryl substituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.007
• 作为产物：
  描述：

  tert-butyl (4-(4-formylphenyl)pyridin-2-yl)carbamate 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 4-(2-aminopyridin-4-yl)benzaldehyde
  参考文献：
  名称：

  Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR

  摘要：

  3,7-Diaryl substituted imidazopyridines were designed and developed as a new class of KDR kinase inhibitors. A variety of imidazopyridines were synthesized and potent inhibitors of KDR kinase activity were identified with good aqueous solubility. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.12.007

文献信息

• Selective Fluorination of 4-Substituted 2-Aminopyridines and Pyridin-2(1<i>H</i>)-ones in Aqueous Solution
  作者：Gang Zhou、Yawei Tian、Xiaoming Zhao、Wenyan Dan

  DOI：10.1021/acs.orglett.8b02003

  日期：2018.8.17

  Fluorination of 2-aminopyridines and pyridin-2(1H)-ones in the presence of Selectfluor, water, and chloroform under mild conditions has been realized. This method gives fluorinated pyridines in good to high yields with high regioselectivities. The electron-deficient pyridine system is activated by an amino or hydroxyl group at C2. The regioselectivity of the fluorination reaction is strongly dependent

  已经实现了在温和条件下在Selectfluor，水和氯仿存在下对2-氨基吡啶和吡啶2（1 H）-1的氟化反应。该方法以高至高产率和高区域选择性得到氟化吡啶。缺电子吡啶系统被C2处的氨基或羟基激活。氟化反应的区域选择性强烈取决于2-氨基吡啶或吡啶-2（1 H）-one中的取代基模式。还实现了3-氟取代的吡啶衍生物到氟化的唑烷嘧啶的转化。
• New 2-amino-pyridinyl-N-acylhydrazones: Synthesis and identification of their mechanism of anti-inflammatory action
  作者：Natalia de Morais Cordeiro、Rosana H.C.N. Freitas、Carlos Alberto Manssour Fraga、Patricia Dias Fernandes

  DOI：10.1016/j.biopha.2019.109739

  日期：2020.3

  AIMS The main aim of this paper was the synthesis and the evaluation of the anti-inflammatory activity of LASSBio-1828 (an amino-pyridinyl-N-acylhydrazone) and its respective hydrochloride, based on a p38α MAPK inhibitor (LASSBio-1824) previously synthesized by our group. MAIN METHODS The compounds were tested regarding their cell viability effect and on acute models of inflammation such as formalin-induced

  目的本文的主要目的是基于以前的p38αMAPK抑制剂（LASSBio-1824）合成和评估LASSBio-1828（一种氨基吡啶基-N-酰基hydr）及其盐酸盐的抗炎活性。由我们小组合成。主要方法测试化合物的细胞活力作用和急性炎症模型，如福尔马林诱导的舔test试验，细胞迁移和炎症介质定量。主要发现用该化合物治疗可抑制p38α，减轻炎性疼痛，细胞迁移和参与MAPK途径的炎性介质，例如TNF-α和IL-1β。综上所述，这些结果表明，LASSBio-1828相应盐酸盐的合成增强了其作为p38抑制剂的功效，
• Tyrosine kinase inhibitors
  申请人：Bilodeau T. Mark

  公开号：US20050176753A1

  公开（公告）日：2005-08-11

  The present invention relates to imidazopyridine compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

  本发明涉及一种咪唑吡啶化合物，其可以抑制、调节和/或调节酪氨酸激酶信号转导，包含这些化合物的组合物以及使用它们治疗哺乳动物中的酪氨酸激酶依赖性疾病和病状的方法，如血管生成、癌症、肿瘤生长、动脉粥样硬化、年龄相关性黄斑变性、糖尿病视网膜病变、炎症性疾病等。
• Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction
  作者：Yizhe Wu、Yu Zhang、Yu Guo、Zhichao Pan、Shichun Zhong、Xinxin Jin、Weihao Zhuang、Sikang Chen、Jian Gao、Wenhai Huang、Xiaowu Dong、Jinxin Che

  DOI：10.1016/j.ejmech.2021.113637

  日期：2021.11
• TYROSINE KINASE INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1503757A2

  公开（公告）日：2005-02-09